Page last updated: 2024-12-10

gv 150013x

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GV 150013X: CCK-B receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5311147
CHEMBL ID329305
CHEBI ID79615
MeSH IDM0288805

Synonyms (18)

Synonym
gv 150013x
n-phenyl-n'-[(3r)-2,3,4,5-tetrahydro-2,4-dioxo-1-phenyl-5-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-1h-1,5-benzodiazepin-3-yl]urea
gv 150013
CHEMBL329305 ,
chebi:79615 ,
1-[(3r)-1-(1-adamantylmethyl)-2,4-dioxo-5-phenyl-1,5-benzodiazepin-3-yl]-3-phenylurea
gtpl3503
gv150013
unii-wsfvpeemno
gv-150013
167355-22-8
urea, n-phenyl-n'-((3r)-2,3,4,5-tetrahydro-2,4-dioxo-1-phenyl-5-(tricyclo(3.3.1.13,7)dec-1-ylmethyl)-1h-1,5-benzodiazepin-3-yl)-
urea, n-phenyl-n'-(2,3,4,5-tetrahydro-2,4-dioxo-1-phenyl-5-(tricyclo(3.3.1.13,7)dec-1-ylmethyl)-1h-1,5-benzodiazepin-3-yl)-, (r)-
WSFVPEEMNO ,
n-(1-(adamantyl-1-methyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl)-n'-phenylurea,(r)-(-)
bdbm50214395
Q27077933
AKOS040748499

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Although prediction of the plasma profile of lipophilic drugs solely on the basis of in vitro data remains an ambitious target, this study shows that the plasma profile of a lipophilic drug can be predicted with appropriate in vitro dissolution data, provided that the absolute bioavailability of the drug is known and the drug has dissolution limited absorption."( Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration.
Dressman, JB; Nicolaides, E; Reppas, C; Symillides, M, 2001
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Differences between products (both in vitro or in vivo) were less pronounced than differences due to media composition (in vitro) or dosing conditions (in vivo)."( Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data.
Dressman, JB; Efthymiopoulos, C; Galia, E; Nicolaides, E; Reppas, C, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzodiazepineA group of heterocyclic compounds with a core structure containing a benzene ring fused to a diazepine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID607816Anxiolytic activity in po dosed mouse measured after 60 mins post dose by black/white box test2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Synthesis and structure-activity relationship of new 1,5-dialkyl-1,5-benzodiazepines as cholecystokinin-2 receptor antagonists.
AID1346883Human CCK2 receptor (Cholecystokinin receptors)2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (38.46)18.2507
2000's6 (46.15)29.6817
2010's2 (15.38)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.54 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]